产品描述
| 产品名称 | Infliximab (anti-TNF-alpha) |
|---|---|
| 规格或纯度 | Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated |
| 特异性 | TNFSF2/TNFa |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 反应种属 | Cynomolgus,Human |
| 抗体类型 | Primary antibody |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | Kappa |
| SDS-PAGE | 27.6 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 186.7 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-AC, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | Lot by Lot |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS编号和信息 | 170277-31-3 |
| Ligand ID | 5004 |
|---|---|
| 名称 | infliximab |
| 别名 | Remicade® |
| 类别 | Antibody |
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 生物活性评价 | Infliximab has been reported to induce an anti-chimeric antibody response in almost 15% of Crohn's disease patients (47 tested) . This indicates that as predicited, humans can mount an immune response to whole murine variable domains, and is the underlying rationale promoting the development of clinical antibodies with variable domains with more human character (i.e. humanised or fully human monoclonal developments). |
| 评价 | Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ). Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 . Biosimilars: NameTrade nameCompanyClinical PhaseIndicationsReferencesinfliximab-dyyb; CT-P13Remsima; Inflectra; FlammegisCelltrion/PfizerApproved (2013 EMA, 2016 FDA)As per reference agentinfliximab-abda; SB2Flixabi; RenflexisMerck/SamsungBioepisApproved (2016 EMA, 2017 FDA)As per reference agent infliximab-qbtx; PF-06438179Ixifi; ZesslyPfizer?SandozApproved (2017 FDA, 2018 EMA)As per reference agentNI-071 Nichi-Iko PharmaceuticalApproved (2017 Japan); Phase 3 US (NCT02990806)As per reference agent BCD-055 BiocadPh 3 (NCT02762838)Rheumatoid arthritis Infliximab-EPIRUS; BOW015InfimabEpirus BiopharmaceuticalsApproved (2014 India); Ph 3 US (NCT02683564)Rheumatoid arthritis infliximab-axxq; ABP710AvsolaAmgenApproved (2019 FDA)As per reference agent STI-002 MabTech/Sorrento Therapeutic Infliximab biosimilar 1 Nippon KayakuApproved (Japan 2014)As per reference agentTwo more biosimilars have been approved in Japan: Infliximab biosimilar 2 (Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical; 2017) and Infliximab biosimilar 3 (Pfizer Japan; 2018), both indicatated as per reference agent . |
| 单字母多肽序列 | |
| 三字母多肽序列 | |
| 翻译后修饰 | |
| 化学修饰 |
ELISA: Infliximab (anti-TNF-alpha) (I412009)
Infliximab (anti-TNF-alpha) (I412009) - ELISA
Immobilized Recombinant Human TNF-alpha Protein (rp156007) at 0.5 μg/mL can bind Infliximab (anti-TNF-alpha) (I412009) with the EC₅₀ of 31.52 ng/mL.
SEC: Infliximab (anti-TNF-alpha) (I412009)
Infliximab (anti-TNF-alpha) (I412009) - SEC
The purity of Infliximab (anti-TNF-alpha) (I412009) is more than 95% verified by HPLC.
